Literature DB >> 19084084

Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.

W Virgil Brown1.   

Abstract

The microvascular complications of diabetes mellitus confer substantial morbidity and impair patient quality of life. Dyslipidemia and prolonged hyperglycemia promote an increase in oxidative stress, inflammation, and vascular damage, which together promote endothelial dysfunction and are associated with macrovascular and microvascular complications. Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease. Diabetic nephropathy is the most common cause of end-stage renal disease in developed countries, and its prevalence is increasing. Preventing or limiting the progression of diabetic nephropathy, as demonstrated in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, may prevent or delay renal complications, as well as convey important cardioprotective benefits in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084084     DOI: 10.1016/j.amjcard.2008.09.068

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  32 in total

1.  Influence of snoring on microalbuminuria in diabetic patients.

Authors:  Duygu Ozol; Ayse Carlıoğlu; Harun Karamanlı; Recep Akgedik; Feridun Karakurt; Zeki Yıldırım
Journal:  Sleep Breath       Date:  2010-07-06       Impact factor: 2.816

2.  Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

Authors:  Ahmed A Elmarakby; Jessica Faulkner; Mohammed Al-Shabrawey; Mong-Heng Wang; Krishna Rao Maddipati; John D Imig
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-10       Impact factor: 3.619

3.  Predictors of and survival after incident stroke in type 1 diabetes.

Authors:  Aaron M Secrest; Catherine T Prince; Tina Costacou; Rachel G Miller; Trevor J Orchard
Journal:  Diab Vasc Dis Res       Date:  2012-04-25       Impact factor: 3.291

4.  Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet.

Authors:  F Li; C-H Wang; J-G Wang; T Thai; G Boysen; L Xu; A L Turner; A S Wolberg; N Mackman; N Maeda; N Takahashi
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

Review 5.  Role of triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  John C Rutledge; Kit F Ng; Hnin H Aung; Dennis W Wilson
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

6.  Gender difference in albuminuria and ischemic heart disease in type 2 diabetes.

Authors:  Manouchehr Nakhjavani; Afsaneh Morteza; Yaser Jenab; Azam Ghaneei; Alireza Esteghamati; Maryam Karimi; Alireza Farokhian
Journal:  Clin Med Res       Date:  2011-10-26

7.  Purple corn anthocyanins retard diabetes-associated glomerulosclerosis in mesangial cells and db/db mice.

Authors:  Jing Li; Min-Kyung Kang; Jin-Kyu Kim; Jung-Lye Kim; Sang-Wook Kang; Soon Sung Lim; Young-Hee Kang
Journal:  Eur J Nutr       Date:  2011-11-20       Impact factor: 5.614

8.  Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue.

Authors:  C Hu; X D Cong; De-Zai Dai; Y Zhang; G L Zhang; Y Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-26       Impact factor: 3.000

9.  Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study.

Authors:  Alex Z Fu; Ying Qiu; Larry Radican; Donald D Yin; Panagiotis Mavros
Journal:  Cardiovasc Diabetol       Date:  2010-04-21       Impact factor: 9.951

10.  Assessment of the Siksika chronic disease nephropathy-prevention clinic.

Authors:  David R R Ward; Ellen Novak; Nairne Scott-Douglas; Sony Brar; Melvin White; Brenda R Hemmelgarn
Journal:  Can Fam Physician       Date:  2013-01       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.